Recruiting

MIRA

Sponsor:

Boninger, Michael, MD

Code:

NCT05768802

Conditions

Amputation

Amputation; Traumatic, Hand

Eligibility Criteria

Sex: All

Age: 22 - 70

Healthy Volunteers: Not accepted

Interventions

Myoelectric Implantable Recording Array (MIRA)

Study Details

Brief summary:

The purpose of this research study is to see how well a new type of myoelectric prosthesis works. A myoelectric prosthesis is a robotic limb for amputees that is controlled by sensing the activity of muscles in the body above the amputation level. This study involves a medical procedure to implant the Myoelectric Implantable Recording Array (MIRA) in the residual limb. The procedure will be performed under sedation by a physician. When muscles contract, they generate an electrical signal that can be sensed by MIRA and used to control the prosthetic limb. Myoelectric prosthetic limbs normally use electrodes that are placed on the surface of the skin to control different movements. However, MIRA is implanted under the skin, which could improve the ability to control the myoelectric prosthesis. After the MIRA is implanted, training will occur to learn how to control the prosthesis using the muscles in the residual limb. The device can stay implanted for up to one year. The device will be removed (explanted) by a physician.

Conditions

Amputation

Amputation; Traumatic, Hand

Study ID

NCT05768802

Start date

Jan 16, 2026

Status verified date

Feb, 2026

Completion date

Dec, 2030

Anticipated

Primary completion date

Dec, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 22 - 70

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Subjects must have a unilateral transradial amputation or wrist disarticulation.
2. Subjects must demonstrate independent voluntary control of muscles in the flexor and extensor compartments of the forearm
3. Subjects must be over 1-year post-amputation at time of implantation.
4. Subjects must be between the ages of 22 and 70 years old. Subjects outside this age range may be at an increased surgical risk and increased risk of fatigue during prosthetic training.
5. Subjects must be able to communicate with the investigators in English because of the need to follow the instructions of the study team.
6. Subjects must show an understanding of the study goals and have the ability to follow simple directions as judged by the investigators.
7. Subjects must pass a neuropsychological and psychosocial assessment.
8. Documentation of informed consent must be obtained from the subject.

Exclusion Criteria:

1. Subjects must be able to function without the use of a prosthesis, or have access to assistance, for a period of 6 weeks following implantation and explantation surgeries.
2. Subjects must not have visual impairment such that extended viewing of a computer monitor would be difficult even with ordinary corrective lenses.
3. Subjects who have another serious disease(s) or disorder(s) that could affect their ability to participate in this study (verified during pre-op anesthesia evaluation to determine surgical risk status) will be excluded.
4. Subjects must not have phantom limb pain that is self-reported to be severe (options are no pain, mild pain, moderate pain, severe pain).
5. Subjects must not have any type of implantable generator such as a pacemaker, spinal cord stimulator, cochlear implant, deep brain stimulator (DBS) or DBS leads, vagus nerve stimulator, or defibrillator.
6. Female subjects of childbearing age must not be pregnant, lactating, or plan to become pregnant during the next 25 months.
7. Subjects must have no history of peripheral vascular disease that could impact wound healing.
8. Subjects who require routine MRI, therapeutic ultrasound, or diathermy as part of their ongoing care will be excluded.
9. Subjects must not have osteomyelitis.
10. Subjects must have no history of intractable clinically relevant cardiac arrhythmias.
11. Subjects must have no active infection(s) or unexplained fever(s) (verified during pre-op anesthesia evaluation to determine surgical risk status).
12. Subject must have no history of ongoing untreated alcoholism.
13. Subject must not be receiving chronic oral or intravenous steroids or immunosuppressive therapy.
14. Subjects must not be receiving medications that affect blood coagulation.
15. Subjects must not have had active cancer within the past year (other than adequately treated basal cell or squamous cell skin cancer) or require chemotherapy.
16. Subjects must not have uncontrolled insulin dependent diabetes mellitus.
17. Subjects who have had a seizure in the last two years will be excluded.
18. Subjects who have attempted suicide in the past 12 months will be excluded.
19. Subjects who are immunosuppressed or who have conditions that typically result in immunocompromise (including, but not limited to: ataxia-telangiectasia, cancer, Chediak-Higashi syndrome, combined immunodeficiency disease, complement deficiencies, DiGeorge syndrome, HIV/AIDS, hypogammaglobulinemia, Job syndrome, leukocyte adhesion defects, malnutrition, panhypogammaglobulinemia, Bruton disease, congenital agammaglobulinemia, selective deficiency of IgA and Wiscott-Aldrich syndrome) will be excluded.
20. Subjects with active psychiatric concerns, including but not limited to major depression, bipolar disorder, schizophrenia or other psychotic disorder and post-traumatic stress disorder. Individuals undergoing effective treatment for any of these disorders will not be excluded, but will be evaluated by a rehabilitation psychologist.
21. Subjects who report use of controlled, non-prescribed substances other than cannabis/marijuana will be excluded. If a subject reports use of cannabis, we will use the DAST-10 questionnaire to screen for level of abuse. An individual may be included if the score is 5 or less and if the neuropsychologist deems that they are eligible. Subjects reporting use of cannabis will also undergo a urine drug test to screen for other nonprescribed drugs. Subjects will be excluded if they test positive for any non-prescribed substance other than cannabis.

Study Design

Enrollment

5 participants

Anticipated

Intervention Model

Single group

Primary purpose

Device Feasibility

Interventions and Outcome Measures

Arms

experimental: MIRA Device

All participants enrolled in the study and who meet eligibility criteria will be implanted with the MIRA device in their residual limb. There is no control group.

Interventions

Myoelectric Implantable Recording Array (MIRA)

The Myoelectric Implantable Recording Array (MIRA) will use electromyography to detect the electrical activity of forearm muscles and transmit that information to an externally-powered prosthetic limb. The MIRA is implanted under the skin.

Primary outcome measure

  • Number of Participants Explanted [ Time Frame: 12 months ]

Central Contacts and Locations

Central contacts

Locations

University of Pittsburgh Medical Center

Recruiting

Pittsburgh, Pennsylvania, United States, 15213

Contacts

More Information

Sponsor

Boninger, Michael, MD

Last update posted

Feb 27, 2026

Last verified

Feb, 2026

Keywords

  • hand amputation
  • wrist amputation
  • transradial amputation

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Boninger, Michael, MD on 2026-02-27.